Atea/AVIR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Atea

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Ticker

AVIR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jean-Pierre Sommadossi

Employees

74

Headquarters

Boston, United States

Atea Metrics

BasicAdvanced
$309M
Market cap
-
P/E ratio
-$1.96
EPS
0.19
Beta
-
Dividend rate
$309M
0.1942
$4.60
$2.77
291K
13.284
-27.48%
-29.16%
-28.78%
0.613
0.613
-49.17%

What the Analysts think about Atea

Analyst Ratings

Majority rating from 3 analysts.
Sell

Atea Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$63M
61.38%
Profit margin
0.00%
NaN%

Atea Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 23.63%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.34
-$0.40
-$0.47
-$0.75
-
Expected
-$0.47
-$0.48
-$0.50
-$0.61
-$0.77
Surprise
-27.66%
-16.08%
-5.37%
23.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Atea stock?

Atea (AVIR) has a market cap of $309M as of June 15, 2024.

What is the P/E ratio for Atea stock?

The price to earnings (P/E) ratio for Atea (AVIR) stock is 0 as of June 15, 2024.

Does Atea stock pay dividends?

No, Atea (AVIR) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Atea dividend payment date?

Atea (AVIR) stock does not pay dividends to its shareholders.

What is the beta indicator for Atea?

Atea (AVIR) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Atea stock price target?

The target price for Atea (AVIR) stock is $2, which is NaN% below the current price of $. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Atea stock

Buy or sell Atea stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing